MMV signs MOU with sanofi-aventis

Collaboration to accelerate research and development of new antimalarials

22 Oct 2008

MMV will collaborate with sanofi-aventis to develop synergies to speed up the R&D of new treatments for malaria. Under the terms of the agreement, sanofi-aventis will share information with MMV on its malaria drugs portfolio that includes the recently WHO pre-qualified fixed-dose combination of artesunate and amodiaquine (Coarsucam®, or “ASAQ”), co-developed with the Drugs for Neglected Diseases initiative (DNDi).”